Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study.

Dardari, Dured; Thomas, Claire; Laborne, Francois-Xavier; Tourte, Caroline; Henry, Elodie; Erblang, Megane; Bourdon, Stéphanie; Penfornis, Alfred; Lopes, Philippe

doi:10.3390/medicina58040555

Public

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study.

Shared by NobleBlocks on Apr 18, 2022 • 12:00 AM UTC

Authors:

Dured Dardari

Claire Thomas

Francois-Xavier Laborne

Abstract

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropat...

Subject

Charcot neuroarthropathy

HbA1c

diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!